Assessment of Immunogenicity and Efficacy of CV0501 mRNA-Based Omicron COVID-19 Vaccination in Small Animal Models.
COVID-19 variant
SARS-CoV-2
mRNA vaccine
virus neutralizing antibody titer
Journal
Vaccines
ISSN: 2076-393X
Titre abrégé: Vaccines (Basel)
Pays: Switzerland
ID NLM: 101629355
Informations de publication
Date de publication:
31 Jan 2023
31 Jan 2023
Historique:
received:
04
01
2023
revised:
27
01
2023
accepted:
28
01
2023
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
1
3
2023
Statut:
epublish
Résumé
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron and its subvariants (BA.2, BA.4, BA.5) represented the most commonly circulating variants of concern (VOC) in the coronavirus disease 2019 (COVID-19) pandemic in 2022. Despite high vaccination rates with approved SARS-CoV-2 vaccines encoding the ancestral spike (S) protein, these Omicron subvariants have collectively resulted in increased viral transmission and disease incidence. This necessitates the development and characterization of vaccines incorporating later emerging S proteins to enhance protection against VOC. In this context, bivalent vaccine formulations may induce broad protection against VOC and potential future SARS-CoV-2 variants. Here, we report preclinical data for a lipid nanoparticle (LNP)-formulated RNActive
Identifiants
pubmed: 36851196
pii: vaccines11020318
doi: 10.3390/vaccines11020318
pmc: PMC9965737
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT05477186']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : CureVac SE
ID : 000000
Organisme : GSK
ID : 000000
Références
Sci Rep. 2022 May 3;12(1):7168
pubmed: 35505068
Vaccines (Basel). 2022 Aug 04;10(8):
pubmed: 36016139
Nature. 2022 Feb;602(7898):671-675
pubmed: 35016199
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
Nat Commun. 2021 Feb 19;12(1):1152
pubmed: 33608538
Nat Med. 2022 Nov;28(11):2398-2405
pubmed: 36357676
Nature. 2022 Feb;602(7898):676-681
pubmed: 35016198
Clin Infect Dis. 2023 Feb 8;76(3):e240-e249
pubmed: 35717657
Nature. 2022 Jan;601(7893):410-414
pubmed: 34794169
Vaccines (Basel). 2022 May 11;10(5):
pubmed: 35632512
Proc Natl Acad Sci U S A. 2017 Aug 29;114(35):E7348-E7357
pubmed: 28807998
Sci Immunol. 2022 Dec 23;7(78):eade9888
pubmed: 36378074
Int J Infect Dis. 2022 Sep;122:758-766
pubmed: 35840098
Nat Commun. 2022 Aug 8;13(1):4610
pubmed: 35941149
Cell. 2023 Jan 19;186(2):279-286.e8
pubmed: 36580913
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
PLoS Pathog. 2022 Jan 13;18(1):e1010161
pubmed: 35025969
Trop Med Infect Dis. 2022 May 22;7(5):
pubmed: 35622708
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
Cell Rep. 2022 Apr 19;39(3):110688
pubmed: 35421378
Nat Med. 2023 Jan;29(1):247-257
pubmed: 36265510
Nat Commun. 2021 Oct 7;12(1):5868
pubmed: 34620866
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Immunol. 2021 Oct;22(10):1306-1315
pubmed: 34417590
Ann Thorac Med. 2022 Apr-Jun;17(2):81-86
pubmed: 35651891
Eur J Nucl Med. 1988;14(7-8):400-2
pubmed: 3053186
Nat Commun. 2021 Jun 30;12(1):4048
pubmed: 34193869
Rev Med Virol. 2022 Sep;32(5):e2381
pubmed: 35856385
Clin Microbiol Infect. 2022 Feb;28(2):202-221
pubmed: 34715347
Science. 2022 Feb 25;375(6583):864-868
pubmed: 35076256
Lancet Infect Dis. 2022 Aug;22(8):1114-1116
pubmed: 35752196
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Viruses. 2022 Jan 30;14(2):
pubmed: 35215887